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INTRODUCTION: 
One of the most feasible approaches for achieving a 
prolonged and predictable drug delivery in the GI tract is 
to control the gastric residence time by using gastro-
retentive dosage forms (GRDFs). It remains in the gastric 
region for several hours and hence prolongs the gastric 
residence time of drug. It has several advantages over 
immediate release dosage form including the 
minimization of fluctuations in drug concentration in 
plasma and at the site of action over prolonged periods of 
time, resulting in optimized therapeutic efficiencies and 
reduce the side effect, reduction of total dose 
administered and reduction of administration frequency 
leading to improved patient compliances1, 2 Gastric 
emptying of dosage forms is an extremely variable 
process and ability to prolong and control the emptying 
time is a valuable asset for dosage forms, which reside in 
the stomach for a longer period of time than conventional 
dosage forms. 
Floating microspheres are gastro-retentive drug delivery 
systems based on non-effervescent approach. These 
microspheres are characteristically free flowing powders 
having a size less than 200 μm and remain buoyant over 
gastric contents and for prolonged period. As the system 
floats over gastric contents, the drug is released slowly at 
desired rate resulting in increased gastric retention with 
reduced fluctuations in plasma drug concentration.3,4 
Captopril is classified as an antihypertensive drug. It has 
mean plasma half-life of 2-3 hour and only 40 % of the 
drug reaches to the systemic circulation due to hepatic 
first pass metabolism. Captopril prevents the conversion 
of angiotensin I to angiotensin II by inhibition of ACE, a 
peptidyldipeptide carboxy hydrolase. This inhibition has 
been demonstrated in both healthy human subjects and in 
animals by showing that the elevation of blood pressure 
caused by exogenously administered angiotensin I was 
attenuated or abolished by captopril. CP has a short half 
life and low bioavailability in the upper part of GIT 
hence it is suitable for gastro-retentive system. 4, 5 
In the present investigation floating microsphere of 
captopril were prepared by solvent evaporation using two 
different polymer hydroxypropylmethyl cellulose 
(HPMC) and ethyl cellulose (EC). The aim of the work 
was to evaluate microspheres for size, in-vitro release, 
buoyancy and incorporation efficiency. The effect of an 
assortment of formulation variables on the size and drug 
release were also investigated. 
MATERIAL & METHODS: 
Materials: 
Active pharmaceutical ingredient: 
Captopril (CP) was obtained as a gift sample from 
Ruskin chemipharm, Mumbai,India  
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Polymers & Reagents: 
HPMC K4M, are provided by Coloron Asia Private 
Limited; Goa. and all polymers and solvents used were 
of pharmaceutical or analytical grade.  
Preparation of floating microspheres:  
Microspheres containing Captopril drug as a core 
material were prepared by a Non-aqueous Solvent 
Evaporation method. Drug, EC and HPMC K4M were 
mixed in the mixture dichloromethane and ethanol at 1:1 
ratio. The slurry was slowly introduced into 100 ml of 
liquid paraffin containing 0.01%. Tween 80 while being 
stirred at 1200 rpm using mechanical stirrer equipped 
with three bladed propellers at room temperature. The 
solution was stirred for 2 hour and allowed the solvent to 
evaporate completely and filtered by using filter paper. 
The microspheres obtained were washed repeatedly with 
petroleum ether (40o-60oC) until free from oil. The 
collected microspheres were dried at room temperature 
and subsequently stored in desiccators. Same procedure 
was repeated for all the three batches.7 
Characterization of microspheres: 
Scanning electron microscopy: 
The external and internal morphology of the 
microspheres were studied using scanning electron 
microscopy (SEM). The samples for SEM were prepared 
by lightly sprinkling on a double adhesive tape stuck to 
an aluminum stub. The stubs were then coated with 
platinum to a thickness of about 10 Å under an argon 
atmosphere using a gold sputter module in a high-
vacuum evaporator. The stub containing the coated 
samples was placed in the scanning electron microscope 
(JSM- 6360A; JEOL, Tokyo, Japan) chamber. The 
samples were then randomly scanned, and 
photomicrographs were taken at the acceleration voltage 
of 20 kV, original magnification 30´ to investigate the 
internal morphology.8 
Buoyancy percentage:  
The microspheres weighed (equivalent to 100 mg) were 
spread over the surface of USP XXIV. Dissolution 
apparatus (Type II) filled with 900 ml of 0.1N HCl 
containing 0.02% of Tween80. The medium was agitated 
with a paddle rotating at 100 rpm for 12h. The floating 
and the settled portions of microspheres were recovered 
separately. The microspheres were dried and weighed. 
Buoyancy percentage was calculated as the ratio of the 
mass of the microspheres that remained floating and the 
total mass of the microspheres.9-11 
Percentage Buoyancy = Microsphere remained floating / 
Total mass of microsphere x 100 
Determination of drug entrapment efficiency:  
Microspheres equivalent to 100 mg of the drug were 
taken for evaluation. The amount of drug entrapped was 
estimated by crushing the microspheres and extracting 
with aliquots of 0.1N HCl repeatedly. The extract was 
transferred to a 100 ml volumetric flask and the volume 
was made up using 0.1N HCl. The solution was filtered 
and the absorbance was measured at 217 nm against 
appropriate blank. The amount of drug entrapped in the 
microspheres was calculated by the following formula: 
12, 13 
Drug entrapment efficiency = Experimental drug content 
/ Theoritical drug content 
In-vitro drug release study: 
 In-vitro dissolution of CP from floating microspheres 
was carried out using the USP dissolution test apparatus 
(Type-I). A weighed amount of floating microspheres of 
CP were filled into a capsule and placed in the basket. 
Dissolution media used was 900 ml of 0.1 N HCI (pH 
1.2) maintained at 37 ± 0.5°C and stirred at 100 rpm. At 
predetermined time intervals, 10 ml of sample was 
withdrawn and replaced with equal amount of 0.1 N HCI 
(pH 1.2). The collected samples were filtered and 
suitably diluted with 0.1 N HCI and analyzed 
spectrophotometricaly at 217 nm to determine the 
amount of drug released in the dissolution medium.14 
Kinetics of drug release: 
The mechanism of release was determined by fitting the 
release data to the different kinetic equations such as 
zero-order, first-order, Higuchi, and Korsmeyer- Peppas 
and finding the R2 values of the release profile 
corresponding to each model.15, 16 
RESULT AND DISCUSSION: 
Scanning electron microscopy: 
The morphology of microspheres was examined using 
SEM. The view of the microspheres showed a hollow 
spherical structure with a smooth surface morphology 
(Figure 1 (a) and (b)) and exhibited a range of sizes 
within each batch. Some of the microspheres showed a 
dented surface structure (Figure 1 (c)), but they showed 
good floating ability on the surface of the medium 
indicating intact surface. The outer surface of the 
microspheres was smooth as shown in figure 1 
illustrating the microphotographs of formulation FM 6. 
The floating microspheres were spherical with no visible 
major surface irregularity. 
 
Particle size analysis: 
The particle size of floating microspheres varied to some 
extent among the formulation due to disparity in the 
symphony of formulations. The effects of stirring speed 
and polymer to polymer ratio on the particle size of 
microspheres are shown in Table 1 and Table 2. 
Formulation FM 6 showed relatively higher percentage 
of large size and formulation FM1 showed relatively 
small size floating microspheres because as viscosity of 
the medium increases at a higher polymer concentration 
resulting in enhanced interfacial tension. Shearing 
efficiency is also diminished at elevated viscosities. This 
outcome in the configuration of larger particles. As 
stirring speed increases from 300 rpm to 1000rpm 
particle size decrease from 272.11 μm to 167.36μm due 
to agitation speed break up the bulk of the polymer into 
finer droplets. 
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Figure 1: SEM of floating microspheres 
 Table 1: Optimization of stirring speed with regards to average particle size and average percent drug 
entrapment 
Batch  Resolution Per Minute  Particle size Drug entrapment 
efficiency 
A 300 272.11±0.75 57.73±1.38 
B 500 212.116±2.32 62.57±0.37 
C 1000 167.36±1.22 39.94±0.85 
 
Table 2: Optimization of polymer ratio with regards to average particle size and average percent drug 
entrapment: 
S.NO Batch 
Code 
HPMC K4M: 
EC 
Mean particle size  
(μm) 
Entrapment 
efficiency (%) 
Buoyancy 
(%)  
Cumulative percentage 
drug release after 12 
hours 
1. FM1 1:1 220.119±1.16 58.11±1.11 71.05±3.4 97.46 
2. FM2 1:2 246.765±2.11 61.09±0.8 74.98±1.7 96.35 
3 FM3 1:3 281.123±2.45 67.34±1.67 80.11±0.8 93.42 
4. FM4 1:4 348.876±0.78 72.89±1.98 82.65±0.4 87.97 
5. FM5 1:5 368.139±18.11 78.65±1.48 87.43±2.3 84.76 
6. FM6 1:6 465.999±0.33 86.12±1.33 89.65±2.2 81.78 
Mean ± S.D., n=3 
Table 3: Interpretation of drug release kinetics of optimized batch FM 6 
 
Drug entrapment efficiency: 
Drug entrapment efficiency was found to be optimum 
(62.57 %) at the stirring speed of 500 rpm. As the stirring 
speed reduced to 300 rpm or increased to 1000 rpm there 
was significant decrease in entrapment efficiency shown 
in Table 1. The entrapment efficiency was found to be 
58.11% to 
86.12% for formulation FM1 to FM6. Drug entrapment 
efficiency was increased with increasing polymer 
concentration in floating microspheres. Results are given 
in Table 2. Among the different polymer-drug ratios 
Batch 
Code 
Zero order First order Higuchi Korsmeyer Peppas 
FM6 R
2
 K0(day
-1
) R
2
 K0(day
-1
) R
2
 K0(day
-1
) R
2
 K0(day
-1
) 
0.783 0.234 0.934 0.011 0.986 4.246 0.978 0.386 
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investigated, 1:6 polymer- drug ratios had the optimum 
capacity for drug encapsulation. 
Buoyancy (%): 
The buoyancy percentage for all batches was almost 
above 75%, which was studied for 12 h. Average 
buoyancy in percentage was found to be 71.05% to 
89.65%. The highest percentage was obtained with 
formulation FM6. In general with increase in the amount 
of polymer (Ethyl Cellulose), there was an increase in 
the buoyancy percentage. From the table 2, it was 
concluded that on increasing ethyl cellulose 
concentration incorporation efficiency and % buoyancy 
increase continuously. 
In-vitro dissolution study: 
Ethyl cellulose is low permeable and water insoluble 
polymer. Floating microspheres showed sustained 
release of the drug in acidic environment and the drug 
release was found to be approximately linear. 
Approximately 15% of the drug was released initially. 
Furthermore, the drug release from the floating 
microspheres matrix was controlled by the polymer. As 
the ethyl cellulose was increased, the release of drug was 
decreased significantly this may be due to increased 
density of the polymer matrix at higher concentrations 
results in an increased diffusional pathlength. This may 
decrease the overall drug release from the polymer 
matrix. Furthermore, smaller microspheres are formed at 
a lower polymer concentration and have a larger surface 
area exposed to dissolution medium, giving rise to faster 
drug release. (Figure 2) 
 
 
Figure 2: % Cumulative drug release of Captopril
Kinetics of drug release: 
The data obtained for in-vitro release were fitted into 
equations for the zero-order, first- order and higuchi 
release models. The interpretation of data was based on 
the value of the resulting regression coefficients. The in-
vitro drug release showed the highest regression 
coefficient values for higuchi model, indicating diffusion 
to be the predominant mechanism of drug release. 
(Table-3) 
Stability studies: 
The samples subjected to stability studies were then 
analyzed. The results of the stability studies (Table 4) 
indicated that the formulations were able to retain their 
stability for a period of 3 months at 40°C/75% RH. 
(Table 4) 
 
Table 4: Stability study 
Days Drug entrapment 
efficiency (%) 
Buoyancy (%) Drug release (%) 
Before storage (0 days) 86.12±1.33 75.48±0.17 81.78±0.23 
After storage 
7 85.78±0.45 75.23±0.23 81.00±0.13 
15 85.56±0.67 75.21±0.89 80.23±0.54 
30 85.34±0.78 75.10±0.45 81.12±0.29 
60 85.00±0.90 75.00±0.17 80.34±0.71 
90 85.00±0.10 75.00±0.28 80.20±0.12 
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CONCLUSION: 
In-vitro data obtained for floating microspheres of 
captopril showed good incorporation efficiency, good 
buoyancy and prolonged drug release. Microspheres of 
different size and drug content could be obtained by 
varying the formulation variables. From the results it can 
be concluded that the drug release from the floating 
microspheres matrix was controlled by the polymer 
proportion. Prepared formulation showed best 
appropriate balance between buoyancy and drug release 
rate. The in-vitro release studies showed that the better 
release profile with the formulation FM6, therefore FM6 
can be considered as best formulation while compared 
with other batches. This can be concluded that by 
formulating captopril as floating microspheres can 
improve the low oral bioavailability by expended drug 
release in the upper part of stomach. 
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